RecruitingNCT05828628
CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
A Prospective Imaging and Translational Tissue Study in CNS Lymphoma to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers
Sponsor
Royal Marsden NHS Foundation Trust
Enrollment
36 participants
Start Date
Sep 18, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
A prospective imaging and translational tissue study in CNS lymphoma to enable further disease characterisation and the development of potential predictive and prognostic biomarkers.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Subjects capable of giving informed consent, or if appropriate, if subject's capacity is deemed limited due to CNS involvement, a consultee can provide consent on their behalf. Some patients with PCNSL may be incapable of providing their own consent due to the neurological effects of their disease. In these cases the patient will be classed as an incapacitated adult and a legal representative will be sought in accordance with English or Scottish law as applicable (see 7.2.1)
- A radiological or histological diagnosis of primary CNS lymphoma.
- Have not received prior CNS directed therapy. Prior use of steroids is permitted.
- Participants aged ≥18 years old.
Exclusion Criteria1
- \- Involvement of lymphoma outside of the CNS
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05828628
Related Trials
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
NCT050986131 location
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
NCT063433112 locations
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
NCT067305421 location
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
NCT068766886 locations
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
NCT053515931 location